TNF Inhibition in Psoriasis and Psoriatic Disease: Long-Term Efficacy and Safety Data Provide the Basis for Clinical Decisions

A supplement to Skin & Allergy News supported by an educational grant from Wyeth and Amgen.
Highlights of presentations that took place at the Skin Disease Education Foundation's 10th International Psoriasis Symposium held June 10-13, 2004, in Toronto, Ontario, Canada.
Skin & Allergy News certifies that this educational activity has been recognized for 1 hour of AAD Category 1 credit and may be used toward the American Academy of Dermatology's Continuing Medical Education Award.

•Contents
•Target Audience
•Educational Needs
•Learning Objectives
•CME Recognition

To view the supplement, click the image above. To take the CME test, download and print out the PDF file, and follow the test instructions on page 12.

Contents

The Role of TNF in Treating Psoriatic Disease
Richard G.B. Langley, MD, FRCPC, Chair
Assistant Professor
Department of Dermatology
Dalhousie University
Director of Research
Department of Dermatology
Queen Elizabeth II Health Sciences Centre
Halifax, Nova Scotia, Canada
Received Funding for Clinical Grants: Amgen, Biogen, Centocor, and Serona S.A.; Consultant: Biogen and Novartis AG.

Clinical Experience Shows Efficacy of TNF Inhibition in Patients with Psoriatic Disease
Alice B. Gottlieb, MD, PhD
Professor of Medicine
Department of Medicine
UMDNJ-Robert Wood Johnson Medical School
Director, Clinical Research Center
W.H. Conzen Chair in Clinical Pharmacology
UMDNJ-Robert Wood Johnson Medical Center
New Brunswick, N.J.
Received Funding for Clinical Grants/Consultant: Abbott Laboratories, Amgen Inc., Biogen Idec, Centocor, Inc., and Genentech, Inc. She discusses the unlabeled use of investigational drugs adalimumab and infliximab for the treatment of psoriasis and psoriatic arthritis.

Safety Data for the TNF Inhibitors: Considerations for the Treatment of Psoriasis and Psoriatic Arthritis
Bruce E. Strober, MD, PhD
Assistant Professor
Ronald O. Perelman Department of Dermatology
New York University School of Medicine
Associate Director, Dermatopharmacology Unit
New York University Medical Center
New York, N.Y.
Consultant: Amgen, Biogen, Fujisawa Healthcare, Inc., and Genentech. He discusses the unlabeled use of the investigational drugs adalimumab and infliximab for the treatment of psoriasis and psoriatic arthritis.

Target Audience

This activity has been developed for dermatologists and other healthcare professionals involved in the identification and treatment of patients with psoriatic disease (skin psoriasis and psoriatic arthritis).

Educational Needs

Tumor necrosis factor (TNF) has been definitively established as a major factor in the development of plaque psoriasis and psoriatic arthritis (PsA). The recognition of this mechanism in psoriatic disease led to the development of TNF-inhibiting biologic drugs. Because dermatologists are in the position to identify patients with plaque psoriasis early in the course of the disease, knowledge about the efficacy and safety of these biologic drugs is essential so that dermatologists can include these agents in their roster of potential therapies.

Learning Objectives

By reading and studying this activity, participants should be able to:

• Discuss the rationale for incorporating biologic therapy for psoriatic disease into the practice of dermatology.

• Explain the immunologic effect of targeting tumor necrosis factor (TNF) in psoriatic disease.

• Discuss the long-term efficacy and safety data regarding TNF-inhibiting drugs in patients with both rheumatoid and psoriatic disease.

CME Recognition

Skin & Allergy News certifies that this educational activity has been recognized for 1 hour of AAD Category 1 credit and may be used toward the American Academy of Dermatology's Continuing Medical Education Award. This program was developed in accordance with the Accreditation Council for Continuing Medical Education guidelines.

Term of Approval: October 2004-September 30, 2005.

Copyright © 2004 by International Medical News Group

---